As of November 6, 2026, Inovio Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: INO); its largest reported holder is Fidelity (FMR), with 14.5% on Schedule 13G/A of November 5, 2026, then Janus Henderson (9.99%). The largest insider holding is Shea Jacqueline Elizabeth, the chief executive and a director, with 111,021 shares (0.11% of shares outstanding), per Form 4 of May 21, 2026 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Inovio Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Inovio Pharmaceuticals, Inc. a real, registered company?
- Inovio Pharmaceuticals Inc files with the SEC under CIK 1055726 (its SEC filings).
- Its shares are listed under the ticker INO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Plymouth Meeting, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under INOVIO PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Inovio Pharmaceuticals, Inc.'s owners and officers?
Inovio Pharmaceuticals, Inc.: incorporated in Delaware; business address in Plymouth Meeting, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 14.5% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 4% |
| Schedule 13G, 2026-08-07 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 10.3% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.05% |
| Schedule 13G/A, 2026-05-15 | Highbridge Capital Management LLC | 8.2% |
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 5.84% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 13.5% |
| Schedule 13G/A, 2026-02-17 | Alyeska Investment Group, L.P. | 5.99% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 4.96% |
| Schedule 13G/A, 2025-12-08 | Janus Henderson Group PLC | 9.99% |
| Schedule 13G, 2025-12-05 | Fmr LLC | 14.8% |
Questions about who owns Inovio Pharmaceuticals, Inc.
Who owns Inovio Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Inovio Pharmaceuticals, Inc.: Fmr LLC (14.5%, Schedule 13G/A, filed 2026-11-05), Janus Henderson Group PLC (9.99%, Schedule 13G/A, filed 2025-12-08), Ra Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-08-07), Highbridge Capital Management LLC (8.2%, Schedule 13G/A, filed 2026-05-15) and Alyeska Investment Group, L.P. (5.99%, Schedule 13G/A, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of Inovio Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Inovio Pharmaceuticals, Inc. on this page are Fmr LLC (14.5%), Janus Henderson Group PLC (9.99%) and Ra Capital Management, L.P. (9.9%).
When did Fmr LLC buy into Inovio Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2025-12-05, reporting 14.8%; its latest, Schedule 13G/A filed 2026-11-05, reports 14.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Inovio Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Inovio Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inovio Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Inovio Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 111,021 shares (0.11% of shares outstanding) (Form 4, 2026-05-21).
- , a director: 87,592 shares (0.08% of shares outstanding) (Form 4, 2026-02-27).
- , the chief scientific officer: 46,823 shares (0.05% of shares outstanding) (Form 4, 2026-05-21).
- , the chief financial officer: 43,229 shares (0.04% of shares outstanding), 42,854 held directly and 375 indirectly (Form 4, 2026-05-21).
- , the chief medical officer: 42,038 shares (0.04% of shares outstanding) (Form 4, 2026-05-21).
Shares outstanding: 103,397,518 as of 2026-08-10, from the company's latest SEC cover page.
How much has Inovio Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Inovio Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Inovio Pharmaceuticals, Inc. and the records around it.
Inovio Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Alyeska Investment Group, L.P. also filed stake reports on 81 other companies: ABUNDIA GLOBAL IMPACT GROUP, INC. (Aug 2026), Bakkt, Inc. (Aug 2026), BATTALION OIL CORP (Aug 2026)
- HIGHBRIDGE CAPITAL MANAGEMENT LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/inovio-pharmaceuticals